Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MAIA Biotechnology, Inc. ( (MAIA) ) has provided an update.
On June 24, 2025, MAIA Biotechnology announced the appointment of two leading oncologists, Dr. Claudia Fulgenzi and Dr. David J. Pinato, to its Scientific Advisory Board. Both specialists in hepatocellular carcinoma (HCC), they will guide the company’s upcoming clinical trials for its lead candidate, ateganosine, in HCC. This strategic move aims to enhance MAIA’s research and development efforts in cancer immunotherapy, particularly in HCC, and follows the company’s receipt of Orphan Drug Designation for ateganosine from the FDA in 2022.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Their lead program involves ateganosine (THIO), a potential first-in-class cancer telomere targeting agent, currently in clinical development for treating non-small cell lung cancer (NSCLC) with telomerase-positive cancer cells.
Average Trading Volume: 291,811
Technical Sentiment Signal: Hold
Current Market Cap: $56.67M
Find detailed analytics on MAIA stock on TipRanks’ Stock Analysis page.